Biodegradable polymer drug-eluting stents: non-inferiority waiting for superiority?

Affiliations

¹ CVPath Institute Inc, 19 Firstfield Road, Gaithersburg, MD 20878, USA; University of Maryland School of Medicine, Baltimore, MD, USA.
² CVPath Institute Inc, 19 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: rvirmani@cvpath.org.

Comment

Aloke V Finn et al. Lancet. 2016.

. 2016 Nov 26;388(10060):2567-2568.

doi: 10.1016/S0140-6736(16)32063-3. Epub 2016 Oct 30.

¹ CVPath Institute Inc, 19 Firstfield Road, Gaithersburg, MD 20878, USA; University of Maryland School of Medicine, Baltimore, MD, USA.
² CVPath Institute Inc, 19 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: rvirmani@cvpath.org.

No abstract available

Comment on

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, Gin RMTJ, Somi S, van Houwelingen KG, Stoel MG, de Man FHAF, Louwerenburg JHW, Hartmann M, Zocca P, Linssen GCM, van der Palen J, Doggen CJM, Löwik MM. von Birgelen C, et al. Lancet. 2016 Nov 26;388(10060):2607-2617. doi: 10.1016/S0140-6736(16)31920-1. Epub 2016 Oct 30. Lancet. 2016. PMID: 27806902 Clinical Trial.